2seventy bio (NASDAQ:TSVT - Get Free Report)'s stock had its "market perform" rating reiterated by equities research analysts at Leerink Partners in a note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock, down from their previous target price of $9.00. Leerink Partners' price target indicates a potential upside of 78.57% from the company's current price.
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of 2seventy bio in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, 2seventy bio currently has an average rating of "Hold" and an average target price of $6.83.
Read Our Latest Report on 2seventy bio
2seventy bio Price Performance
NASDAQ TSVT opened at $2.80 on Tuesday. The stock has a market capitalization of $144.45 million, a P/E ratio of -1.51 and a beta of 1.73. The firm's 50-day moving average is $2.60 and its two-hundred day moving average is $3.69. 2seventy bio has a 12 month low of $2.29 and a 12 month high of $5.99.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new stake in 2seventy bio during the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of 2seventy bio during the fourth quarter worth $32,000. BNP Paribas Financial Markets acquired a new stake in shares of 2seventy bio in the fourth quarter valued at $35,000. ProShare Advisors LLC purchased a new position in 2seventy bio in the fourth quarter valued at $48,000. Finally, Raymond James Financial Inc. purchased a new position in 2seventy bio in the fourth quarter valued at $52,000. Hedge funds and other institutional investors own 93.90% of the company's stock.
2seventy bio Company Profile
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
